GAITHERSBURG, Md., May 24 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that it will announce results from the Phase 1 trial of its patch-based needle-free influenza vaccine before the markets open tomorrow. A conference call and live webcast will be held at 8:30 a.m. Eastern Time tomorrow to discuss the results.
Conference Call Details
To access the live conference call Friday, May 25, 2007 at 8:30 a.m. Eastern Time via phone, please dial 888-396-2356 from the United States and Canada or 617-847-8709 internationally. The conference ID is 63780500. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through June 1, 2007 and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 75528925.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company’s website at http://www.iomai.com . Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea. For more information on Iomai, please visit http://www.iomai.com.
Iomai Corporation
CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel, of Iomai Corporation, +1-301-556-4478,investors@iomai.com; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, breid@weisscommpartners.com, for Iomai Corporation
Web site: http://www.iomai.com/
